{"protocolSection":{"identificationModule":{"nctId":"NCT01388738","orgStudyIdInfo":{"id":"CIB-NBS-C"},"organization":{"fullName":"Clinical Institute of the Brain, Russia","class":"OTHER"},"briefTitle":"Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.","officialTitle":"Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.","acronym":"3C"},"statusModule":{"statusVerifiedDate":"2011-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-01"},"primaryCompletionDateStruct":{"date":"2011-10","type":"ACTUAL"},"completionDateStruct":{"date":"2011-11","type":"ACTUAL"},"studyFirstSubmitDate":"2011-06-27","studyFirstSubmitQcDate":"2011-07-06","studyFirstPostDateStruct":{"date":"2011-07-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-12-22","lastUpdatePostDateStruct":{"date":"2011-12-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"prof. Andrey A. Belkin, MD, PhD","oldOrganization":"Clinical Institute of the Brain, Russia"},"leadSponsor":{"name":"Clinical Institute of the Brain, Russia","class":"OTHER"},"collaborators":[{"name":"Nycomed","class":"INDUSTRY"},{"name":"Veropharm","class":"INDUSTRY"},{"name":"Ever Neuro Pharma GmbH","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Ischemic stroke (IS) causes high mortality and severe disability. To improve outcome it's very important to choose the right way of the management of the patient and an appropriate drugs.\n\nThere is a large number of the so-called neuroprotective drugs, which were effective in laboratory, but didn't show positive results in clinical studies with using traditional clinical scales scores as a primary outcome measures.\n\nSpecialists suggest, that the investigators could receive better results if the investigators change design of the studies, particularly if the investigators select more precise and sensitive method of assessment.\n\nAim of this study: to determine the role of navigated brain stimulation (NBS) for evaluation of the changes in the motor centers and motor tracts after administration of different cerebroprotective drugs. (The substances won't be compared to each other)."},"conditionsModule":{"conditions":["Stroke"],"keywords":["Navigation Brain Stimulation (NEXSTIM)","cerebroprotective drug effectiveness","acute ischemic stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"cerebrolysin","type":"ACTIVE_COMPARATOR","description":"IV","interventionNames":["Drug: cerebrolysin"]},{"label":"L-Alpha glycerylphosphorylcholine","type":"ACTIVE_COMPARATOR","description":"IV","interventionNames":["Drug: L-Alpha glycerylphosphorylcholine"]},{"label":"citicoline","type":"ACTIVE_COMPARATOR","description":"IV and per os","interventionNames":["Drug: citicoline"]}],"interventions":[{"type":"DRUG","name":"citicoline","description":"citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\\*3 times per day) per os","armGroupLabels":["citicoline"]},{"type":"DRUG","name":"L-Alpha glycerylphosphorylcholine","description":"choline alfoscerate IV 1000mg daily 10 days","armGroupLabels":["L-Alpha glycerylphosphorylcholine"]},{"type":"DRUG","name":"cerebrolysin","description":"Cerebrolysin IV 10 ml daily 10 days","armGroupLabels":["cerebrolysin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"MEP(motor evoked potential) parameter: motor threshold","timeFrame":"2 months"},{"measure":"MEP(motor evoked potential) parameter: latency","timeFrame":"2 months"},{"measure":"MEP(motor evoked potential) parameter: amplitude","timeFrame":"2 months"}],"secondaryOutcomes":[{"measure":"Medical Research Council (MRC) Scale for Muscle Strength scores","timeFrame":"2 months"},{"measure":"Barthel index","timeFrame":"2 months"},{"measure":"Modified Rankin Scale (mRS)","timeFrame":"2 months"},{"measure":"Number of Participants with Adverse Events","timeFrame":"2 months"},{"measure":"Change from Baseline in Alpha waves percentage","description":"EEG parameter","timeFrame":"2 months"},{"measure":"Change from Baseline in Beta waves percentage","description":"EEG parameters","timeFrame":"2 months"},{"measure":"Change from Baseline in Delta waves percentage","description":"EEG parameter","timeFrame":"2 months"},{"measure":"Change from Baseline in Theta waves percentage","description":"EEG parameter","timeFrame":"2 months"},{"measure":"Presence of the abnormal epileptiform activity","description":"EEG parameters","timeFrame":"2 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients from 3 to 6 months after ischemic stroke\n* hemispheric infarction\n* paresis from 2 to 4 scores by Medical Research Council Weakness Scale (MRC)\n\nExclusion Criteria:\n\n* history of seizures\n* pregnancy, lactation\n* cognitive deficiency (poor compliance)\n* acute renal failure\n* acute hepatic failure\n* oncological history\n* cardiac pacemakers and other metal implants\n* regular intake of any nootropic drugs\n* Modified Ashford Scale scores 3 and more\n* regular intake of anticonvulsants, neuromuscular relaxants","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Clinical Institute of Brain","city":"Ekaterinburg","state":"Sverdlovsk region","zip":"620102","country":"Russian Federation","geoPoint":{"lat":56.8519,"lon":60.6122}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000006952","term":"Cerebrolysin"},{"id":"D000003566","term":"Cytidine Diphosphate Choline"}],"ancestors":[{"id":"D000018697","term":"Nootropic Agents"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M5724","name":"Choline","relevance":"LOW"},{"id":"M6461","name":"Cytidine Diphosphate Choline","asFound":"Rod","relevance":"HIGH"},{"id":"M351658","name":"Cerebrolysin","asFound":"VII","relevance":"HIGH"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"T443","name":"Choline","relevance":"LOW"}],"browseBranches":[{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"Gast","name":"Gastrointestinal Agents"},{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":false}